Please ensure Javascript is enabled for purposes of website accessibility

Why Curis Fell Off a Cliff on Friday

By Eric Volkman - Jun 11, 2021 at 5:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company will bring a lower dose of an important pipeline drug into a phase 2 clinical trial.

What happened

Cancer drug specialist Curis (CRIS 7.48%) had a Friday to forget. The biotech's share price took a nearly 37% hit after the company reported some disquieting news about a leading pipeline drug.

So what

Friday morning, Curis published updated data from a phase 1/2 clinical trial of its CA-4948, a drug targeting acute myeloid leukemia and myelodysplastic syndromes. The primary endpoint of the trial, which involved 22 participants, was to determine the treatment's maximum tolerated and recommended dose for a phase 2 study.

Cancer attacking an organism.

Image source: Getty Images.

In the trial, the orally administered monotherapy showed dose-limiting toxicities and was administered in 200, 300, 400, and 500 milligram versions. The latter two showed toxicities, therefore Curis decided the upcoming phase 2 trial will involve the 300 milligram dose.

In the update, the biotech's CEO James Dentzer pointed out that the new data "further support the growing body of evidence that CA-4948's anti-cancer activity continues to deepen the longer patients remain on drug, which is enabled by its safety and durability profile to date."

Now what

While such words are encouraging, it's clear investors are deeply concerned about those toxicities. Previously, CA-4948 had seemed to hold more promise -- an earlier-stage study involving nine individuals showed a reduction of abnormal white blood cells in eight of them. That was greeted positively by a hopeful market, but that was then and this is now, and it seems investors are losing that hope.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Curis, Inc. Stock Quote
Curis, Inc.
$1.15 (7.48%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.